Cited by 580Cerebrospinal fluid and hydrocephalusAlzheimer's disease research and treatmentsBarrier Structure and Function Studies

Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease

Open access
Peng, Weiguo, Achariyar, Thiyagarajan M., Li, Baoman, Liao, Yonghong, Mestre, Humberto, Hitomi, Emi, Regan, Sean, Kasper, Tristan +5 more·2016·Neurobiology of Disease

Abstract

Glymphatic transport, defined as cerebrospinal fluid (CSF) peri-arterial inflow into brain, and interstitial fluid (ISF) clearance, is reduced in the aging brain. However, it is unclear whether glymphatic transport affects the distribution of soluble Aβ in Alzheimer's disease (AD). In wild type mice, we show that Aβ40 (fluorescently labeled Aβ40 or unlabeled Aβ40), was distributed from CSF to brain, via the peri-arterial space, and associated with neurons. In contrast, Aβ42 was mostly restricted to the peri-arterial space due mainly to its greater propensity to oligomerize when compared to Aβ40. Interestingly, pretreatment with Aβ40 in the CSF, but not Aβ42, reduced CSF transport into brain. In APP/PS1 mice, a model of AD, with and without extensive amyloid-β deposits, glymphatic transport was reduced, due to the accumulation of toxic Aβ species, such as soluble oligomers. CSF-derived Aβ40 co-localizes with existing endogenous vascular and parenchymal amyloid-β plaques, and thus, may contribute to the progression of both cerebral amyloid angiopathy and parenchymal Aβ accumulation. Importantly, glymphatic failure preceded significant amyloid-β deposits, and thus, may be an early biomarker of AD. By extension, restoring glymphatic inflow and ISF clearance are potential therapeutic targets to slow the onset and progression of AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2016.05.015

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Inhibition of glymphatic transport leads to significant accumulation of Aβ in APP/PS1 mouse brain.

    “Moreover, inhibition of glymphatic transport leads to a significant accumulation of Aβ in APP/PS1 mouse brain [415].”
  • Infusion of amyloid-β into CSF acutely reduces glymphatic activity in wild-type mice, suggesting a direct toxic effect.

    “Infusion of amyloid-β into CSF acutely reduced glymphatic activity in wild-type mice suggesting a direct toxic effect (50, 55).”

    From Glymphatic failure as a final common pathway to dementia (2020) · cites this paper as [55]

  • Glymphatic CSF influx and CSF clearance are reduced in early amyloid deposition in the APP/PS1 Alzheimer disease model compared with littermate controls, and CSF clearance continues to decline as amyloid burden increases.

    “glymphatic CSF influx and CSF clearance are each reduced in early stages of amyloid deposition in the APP/PS1 model of Alzheimer disease, compared with littermate controls; CSF clearance continues to decline as the amyloid burden increases (Fig. 1b).”

    From Glymphatic failure as a final common pathway to dementia (2020) · cites this paper as [55]

  • Both the brain glymphatic and meningeal lymphatic systems deteriorate with age and their dysfunction can potentiate AD pathology and dementia.

    “both the brain glymphatic and meningeal lymphatic systems deteriorate with age”

    From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Peng et al., 2016

  • In the APP/PS1 mouse model of AD, glymphatic dysfunction as measured by CSF clearance rates was impaired, and injection of amyloid-β into the CSF reduced glymphatic activity.

    “In the APP/PS1 mouse model of AD, glymphatic dysfunction as measured by CSF clearance rates was impaired”

    From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Peng et al., 2016

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Peng, W., Achariyar, T. M., Li, B., Liao, Y., Mestre, H., Hitomi, E., Regan, S., Kasper, T., Peng, S., Ding, F., Benveniste, H., Nedergaard, M., & Deane, R.
Affiliations
  • University of Rochester Medicine (US)
  • Stony Brook University (US)
Corresponding author
Deane, Rashid
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2016-09
Volume
93
Pages
215-225
ISSN
0969-9961 (ISSN-L)
OpenAlex
W2397614738
Cited by
580
References
76
Citations by year
2026: 59 · 2025: 61 · 2024: 92 · 2023: 69 · 2022: 76 · 2021: 55 · 2020: 52 · 2019: 48 · 2018: 44 · 2017: 20 · 2016: 3
FWCI
21.50
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Disease (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke
  • National Institute of Aging
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
glymphatic system, Alzheimer's disease, cerebrospinal fluid, interstitial fluid clearance, amyloid-beta, Aβ40, amyloid-beta 42, amyloid oligomers, APP/PS1 mice, cerebral amyloid angiopathy, amyloid plaques, early biomarkers, therapeutic target
MeSH terms
Alzheimer Disease, Animals, Biological Transport, Brain, Disease Models, Animal, Mice, Inbred C57BL, Neurons, Amyloid beta-Peptides, Disease Progression, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review